The role of carnitine supplementation during valproic acid therapy

Annals of Pharmacotherapy

Volumn 34, Issue 5, 2000, Pages 630-638

  Raskind, Jackie Y ^a,b   El Chaar, Gladys M ^a,c  

^a ST JOHN'S UNIVERSITY   (United States)

^b BRIDGEPORT HOSPITAL   (United States)

^c SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

Camitine; Hepatotoxicity; Hyperammonemia; Valproic acid

Indexed keywords

CARNITINE; VALPROIC ACID;

AMINO ACID BLOOD LEVEL; ANTICONVULSANT THERAPY; CARNITINE DEFICIENCY; CLINICAL FEATURE; DIET SUPPLEMENTATION; EPILEPSY; HUMAN; HYPERAMMONEMIA; LIVER TOXICITY; MEDICAL LITERATURE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0034018410     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19242     Document Type: Review

References (36)

1. Browne TR. Valproic acid. N Engl J Med 1980;302:661-6.
2. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. US experience since 1984. Neurology 1989;39(2 pt 1):201-7.
3. Coulter DL. Carnitine, valproate and toxicity. J Child Neurol 1991;6:7-14.
4. Goa KL, Brogden RN. L-Carnitine. Drugs 1987;34:1-24.
5. Pons R, De Vivo DC. Primary and secondary carnitine deficiency syndromes. J Child Neural 1995;10(Suppl 2):S8-24.
6. Carter AL, Abney TO, Lapp DF. Biosynthesis and metabolism of carnitine. J Child Neurol 1995;1(Suppl 2):S3-7.
7. DeVivo DC, Bohan TP, Coulter DL, Dreifuss FE, Greenwood RS, Nordli DR, et al. L-Carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998;39:1216-25.
8. Coulter DL. Carnitine deficiency in epilepsy: risk factors and treatment. J Child Neurol 1995;10(Suppl 2):S32-9.
9. Matsuda I, Ohtani Y. Carnitine status in Reye and Reye-like syndromes. Pediatr Neurol 1986;2:90-4.
10. Coulter DL. Carnitine deficiency: a possible mechanism for valproate hepatotoxicity (letter). Lancet 1984;1:689.
11. Bohles H, Sewell AC, Wenzel D. The effect of carnitine supplementation in valproate-induced hyperammonaemia. Acta Paedialr 1996;85:446-9.
12. Gidal BE, Inglese CM, Meyer JF, Pitterle ME, Antanopolous J, Rust RS. Diet-and valproate-induced transient hyperammonemia: effect of L-carnitine. Pediatr Neurol 1997;16:301-5.
13. Laub MC, Paetzke-Brunner I, Jaeger G. Serum carnitine during valproic acid therapy. Epilepsia 1986;27:559-62.
14. Coulter DL. Prevention of hepatotoxicity recurrence with valproate monotherapy and carnitine (abstract). Ann Neurol 1988;24:301.
15. Vance CK, Vance WH, Winter SC, Opala G, Szabo A. Control of valproate-induced hepatotoxicity with carnitine (letter). Ann Neurol 1989; 26:456.
16. Murphy JV, Groover RV, Hodge C. Hepatoxic effects in a child receiving valproate and carnitine. J Pediatr 1993;123:318-20.
17. Murakami K, Sugimoto T, Woo M, Nishida N, Muro H. Effect of L-carnitine supplementation on acute valproate intoxication. Epilepsia 1996; 37:687-9.
18. Ishikura H, Matsuo N, Matsubara M, Ishihara T, Takeyama N, Tanaka T. Valproic acid overdose and L-carnitine therapy. J Anal Toxicol 1996;20: 55-8.
19. Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982;101:782-5.
20. Morita J, Yuge K, Yoshino M. Hypocarnitinemia in the handicapped individual who receives polypharmacy of antiepileptic drugs. Neuropediatrics 1986;86:203-5.
21. Melegh B, Kerner J, Kispal G, Ascadi G, Dani M. Effect of chronic valproic acid treatment on plasma and urine carnitine concentrations in children: decreased urinary excretion. Acta Paediatr Hung 1987;28:137-42.
22. Rodriguez-Segade S, de la Pena CA, Tutor JC, Paz JM, Fernandez MP, Rozas I, et al. Carnitine deficiency associated with anticonvulsant therapy. Clin Chim Acta 1989;181:175-81.
23. Beghi E, Bizzi A, Codegoni AM, Trevisan D, Torri W, Collaborative Group for the Study of Epilepsy. Valproate, carnitine metabolism, and biochemical indicators of liver function. Epilepsia 1990;31:346-52.
24. Opala G, Winter S, Vance C, Vance H, Hutchinson HT, Linn LS. The effect of valproic acid on plasma carnitine levels. Am J Dis Child 1991; 145:999-1001.
25. Thom H, Carter PE, Cole GF, Stevenson KL. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev Med Child Neurol 1991;33:795-802.
26. Hug G, McGraw CA, Bates SR, Landrigan EA. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, carbamazepine in children. J Pediatr 1991;119: 799-802.
27. Riva R, Albani F, Gobbi G, Santucci M, Baruzzi A. Carnitine disposition before and during valproate therapy in patients with epilepsy. Epilepsia 1993;34:184-7.
28. Van Wouwe JP. Carnitine deficiency during valproic acid treatment. Int J Vitam Nutr Res 1995;65:211-4.
29. Zelnik N, Fridkis I, Gruener N. Reduced carnitine and antiepileptic drugs: cause relationship or co-existence. Acta Paediatr 1995;84:93-5.
30. Freeman JM, Vining EP, Cost S, Singhi P. Does carnitine administration improve the symptoms attributed to anticonvulsant medications? A double-blinded, cross over study. Pediatrics 1994;93(6 pt 1):893-5.
31. Altunbasak S, Baytok V, Tasouji M, Herguner O, Burgut R, Kayrin L. J Child Neurol 1997;12:461-3.
32. McCurdy HT. Carnitine deficiency (letter). Pediatrics 1995;96:1174-5.
33. Hirose S, Mitsudome A, Yasumoto S, Ogawa A, Muta Y, Tomada Y. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics 1998;101:E1-9.
34. Willmore J, Triggs WJ, Pellock JM. Valproate toxicity: risk screening strategies. J Child Neurol 1991;6:3-6.
35. Konig SA, Siemes H, Blaker F, Boenigk E, Gross-Selbeck G, Hanefeld F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994;35:1005-15.
36. Carnidale V, ed. 2000 Drug topics red book. Montvale, NJ: Medical Economics, 2000.